Prescribing Pattern and Safety of Immunosuppressants in Renal Transplant Patients: An Observational Study.
adverse drug reactions (adr)
immunosuppressant
induction therapy
maintenance therapy
prescribing pattern
renal transplantation
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
29
09
2023
medline:
31
10
2023
pubmed:
31
10
2023
entrez:
31
10
2023
Statut:
epublish
Résumé
Renal transplantation is a life-saving procedure and contributes to a better quality of life in patients with end-stage renal disease. The discovery and use of immunosuppressants to prevent and treat allograft rejection are responsible for the improved outcome after the transplant. Long-term usage of these drugs warrants special monitoring and follow-up of the adverse drug reactions developed during the post-transplant period. This study analyzes the prescribing pattern and severity and outcome of adverse drug reactions of immunosuppressants in renal transplant patients. A cross-sectional, observational study was done in patients more than 18 years of age who have undergone renal transplantation and receiving immunosuppressants in the Department of Nephrology in a tertiary care hospital. During the two-month study period, 150 post-transplant patients were screened for adverse drug reactions, and the prescription pattern was also studied. Immunosuppressive therapy was given as induction and maintenance therapy. The short-term induction therapy regimen was based on the type of donor (injection basiliximab or anti-thymocyte globulin). The long-term maintenance therapy comprises triple therapy of tacrolimus, mycophenolate mofetil, and prednisolone in 102 (68%) patients and cyclosporine, mycophenolate mofetil, prednisolone in 37 (25%) patients. A total of 116 adverse drug reactions were reported in 82 patients. The pattern of the adverse drug reactions showed urinary tract infections in 26 (17.3%) patients on tacrolimus-based regimen and hypertension in 20 (13.3%) patients on tacrolimus and cyclosporine-based regimen. Causality assessment using the World Health Organization causality assessment scale showed that the observed reactions were of probable 42 (36%) and possible 74 (64%) categories. Long-term intake of immunosuppressive drugs is essential to improve the quality of life in renal transplant individuals and it is essential to monitor adverse drug reactions of these drugs through vigilant self-reporting and pharmacovigilance practices.
Sections du résumé
BACKGROUND
BACKGROUND
Renal transplantation is a life-saving procedure and contributes to a better quality of life in patients with end-stage renal disease. The discovery and use of immunosuppressants to prevent and treat allograft rejection are responsible for the improved outcome after the transplant. Long-term usage of these drugs warrants special monitoring and follow-up of the adverse drug reactions developed during the post-transplant period. This study analyzes the prescribing pattern and severity and outcome of adverse drug reactions of immunosuppressants in renal transplant patients.
MATERIALS AND METHODS
METHODS
A cross-sectional, observational study was done in patients more than 18 years of age who have undergone renal transplantation and receiving immunosuppressants in the Department of Nephrology in a tertiary care hospital.
RESULTS
RESULTS
During the two-month study period, 150 post-transplant patients were screened for adverse drug reactions, and the prescription pattern was also studied. Immunosuppressive therapy was given as induction and maintenance therapy. The short-term induction therapy regimen was based on the type of donor (injection basiliximab or anti-thymocyte globulin). The long-term maintenance therapy comprises triple therapy of tacrolimus, mycophenolate mofetil, and prednisolone in 102 (68%) patients and cyclosporine, mycophenolate mofetil, prednisolone in 37 (25%) patients. A total of 116 adverse drug reactions were reported in 82 patients. The pattern of the adverse drug reactions showed urinary tract infections in 26 (17.3%) patients on tacrolimus-based regimen and hypertension in 20 (13.3%) patients on tacrolimus and cyclosporine-based regimen. Causality assessment using the World Health Organization causality assessment scale showed that the observed reactions were of probable 42 (36%) and possible 74 (64%) categories.
CONCLUSIONS
CONCLUSIONS
Long-term intake of immunosuppressive drugs is essential to improve the quality of life in renal transplant individuals and it is essential to monitor adverse drug reactions of these drugs through vigilant self-reporting and pharmacovigilance practices.
Identifiants
pubmed: 37905288
doi: 10.7759/cureus.46200
pmc: PMC10613428
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e46200Informations de copyright
Copyright © 2023, Ragavanandam et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Transplant. 2021 Aug;21(8):2824-2832
pubmed: 33346917
BMJ Case Rep. 2023 May 31;16(5):
pubmed: 37258048
Curr Drug Saf. 2016;11(2):156-63
pubmed: 27194037
Drugs R D. 2023 Aug 22;:
pubmed: 37606750
Ther Drug Monit. 2020 Dec;42(6):811-820
pubmed: 32657909
Kidney Int. 2004 Jul;66(1):433-40
pubmed: 15200453
Int J Organ Transplant Med. 2020;11(4):185-195
pubmed: 33335699
Pak J Pharm Sci. 2023 May;36(3):713-721
pubmed: 37580918
Nefrologia (Engl Ed). 2023 May-Jun;43(3):281-292
pubmed: 37635014
Curr Drug Saf. 2023;18(4):448-464
pubmed: 36200243
Transpl Immunol. 2023 Jun;78:101832
pubmed: 37004886
Exp Clin Transplant. 2019 Jan;17(Suppl 1):78-82
pubmed: 30777528